- Home
- FHTX vs BYRN Comparison
FHTX vs BYRN Comparison
Compare FHTX & BYRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FHTX | BYRN |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Industrial Machinery/Components |
| Sector | Health Care | Miscellaneous |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.2M | 311.6M |
| IPO Year | 2020 | 2013 |
Fundamental Metrics
Financial Performance| Metric | FHTX | BYRN |
|---|---|---|
| Price | $4.89 | $9.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 3 |
| Target Price | $11.50 | ★ $34.67 |
| AVG Volume (30 Days) | 155.6K | ★ 313.0K |
| Earning Date | 03-11-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.32 | N/A |
| EPS | N/A | ★ 0.40 |
| Revenue | ★ $30,909,000.00 | $16,566,295.00 |
| Revenue This Year | $16.83 | $18.33 |
| Revenue Next Year | $15.06 | $17.23 |
| P/E Ratio | ★ N/A | $22.63 |
| Revenue Growth | 36.75 | ★ 1692.08 |
| 52 Week Low | $2.94 | $8.85 |
| 52 Week High | $6.95 | $33.56 |
Technical Indicators
Market Signals| Indicator | FHTX | BYRN |
|---|---|---|
| Relative Strength Index (RSI) | 40.15 | 27.74 |
| Support Level | $4.47 | N/A |
| Resistance Level | $5.85 | $21.98 |
| Average True Range (ATR) | 0.33 | 0.50 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 21.81 | 2.08 |
Price Performance
Historical ComparisonAbout FHTX Foghorn Therapeutics Inc.
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
About BYRN Byrna Technologies Inc.
Byrna Technologies Inc is a designer, manufacturer, retailer, and distributor of technological solutions for security situations that do not require the use of lethal force. The company generates its revenue from the United States, South Africa, Europe, South America, Asia, and Canada.